US 2019/0167596 A1 · Sustained Release Compositions Comprising Micronized Tolcapone

Abstract

The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.

Claims18

Dependent claims

A sustained release tablet comprising micronized tolcapone, a release retardant and a binder.

Dependencies are inferred from the claim text.

Facts

Application

16/321,336Filed 28 Jul 2017

Priority

EP 168382372.729 Jul 2016

Published

6 Jun 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61K 9/2054
Polysaccharides, e.g. alginate, gums; Cyclodextrin: cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
A61K 9/2009
Excipients; Inactive ingredients: inorganic compounds
A61K 9/2013
Excipients; Inactive ingredients: organic compounds, e.g. phospholipids, fats
A61K 9/2095
Pills, tablets, discs, rods: tabletting processes

Sustained Release Compositions Comprising Micronized Tolcapone

Life of this patent

Sustained Release Compositions Comprising Micronized Tolcapone

Life of this patent

Abstract

Claims18